middle.news

Neurizon Taps Global Pharma Leader Before ALS Trial Results

9:02am on Monday 7th of September, 2026 AEST • Biotechnology
Read Story

Neurizon Taps Global Pharma Leader Before ALS Trial Results

9:02am on Monday 7th of September, 2026 AEST
Key Points
  • Dr Chris Bremer to become CEO on 1 October 2026
  • NUZ-001 trial results expected in late Q2 2027
  • More than 20 years of pharmaceutical and biotechnology leadership
  • Over US$1 billion in licensing transactions executed
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE